MILFORD, Mass., Aug. 18, 2011 /PRNewswire/ -- SeraCare Life Sciences (NASDAQ: SRLS), a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, today announced that the Company has introduced three new, differentiated panels to its product portfolio -- an HIV/HCV/HBV Nucleic Acid Qualification Panel, an HIV-1 RNA Linearity Panel and an Anti-HIV-2 Performance Panel.
(Logo: http://photos.prnewswire.com/prnh/20110324/NE70714LOGO )
"New products play an important role in maintaining our competitive advantage, particularly as the market seeks to consolidate suppliers," said Greg Gould, Interim Chief Executive Officer and Chief Financial Officer. "Continually adding innovative products to our portfolio helps grow our business within our current customer base and creates opportunities to expand into new markets and applications. We look forward to continuing to add to our offerings over the course of the year."
New product highlights:
- The HIV/HCV/HBV Nucleic Acid Qualification Panel is designed to compete favorably in the market by combining all three of the most commonly tested disease markers for both blood-donor screening and diagnostic testing in a single panel. This new panel offers increased fill size and is priced competitively to encourage rapid adoption.
- The HIV-1 RNA Linearity Panel replaces a previous panel in SeraCare's portfolio and is now quantified in International Units based on the new World Health Organization standards, allowing customers to compare results across platforms.
- The Anti-HIV-2 Performance Panel upgrades a previous panel to demonstrate results with fourth generation antigen/antibody HIV tests currently on the market. HIV-2 is much rarer than HIV-1, making qualification and acceptance testing with HIV-2 more difficult as materials are harder to find. SeraCare's HIV-2 performance panel provides customers an easy source for HIV-2, uniquely positioning SeraCare to fulfill an unmet need in the marketplace.
About SeraCare Life Sciences, Inc.
SeraCare serves the global life sciences industry by providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics. The Company's innovative portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers, biobanking and contract research services. SeraCare's quality systems, scientific expertise and state-of-the-art facilities support its customers in meeting the stringent requirements of the highly regulated life sciences industry. www.seracare.com
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about SeraCare Life Sciences, Inc. ("SeraCare" or the "Company"). For example, all statements regarding the future of our recently introduced and anticipated new products are forward-looking statements. In addition, forward-looking statements include statements in which we use words such as "expect," "believe," "anticipate," "intend," or similar expressions. Actual results may differ materially from those reflected in the forward-looking statements. Factors that could cause our actual results to differ from the expectations reflected in the forward-looking statements in this press release include, but are not limited to, the risk that our new products do not produce the revenues we anticipate, the risk that sales of our new products may be slower than we expect, the risk that the introduction of new products may be delayed, and uncertainty regarding market acceptance of our new products. Many of these factors are beyond our ability to control or predict.
Gregory A. Gould
Interim Chief Executive Officer
Chief Financial Officer
SeraCare Life Sciences, Inc.
MacDougall Biomedical Communications
SOURCE SeraCare Life Sciences, Inc.